Drug Trial Radar · NCT05583227
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
368
Actual
Start
Nov 10, 2022
Primary completion
Jul 14, 2026
Study completion Mar 23, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
Conditions
- Eosinophilic Esophagitis
Interventions
TezepelumabBiological
Tezepelumab subcutaneous injection
TezepelumabBiological
Tezepelumab subcutaneous injection
PlaceboOther
Placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levelsTime frame: Week 24
- Change from baseline in DSQ (Dysphagia Symptom Questionnaire) scoreTime frame: Week 24
Locations
124 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Little Rock, Arkansas
Research Site
Los Angeles, California
Research Site
Aurora, Colorado
Research Site
Inverness, Florida
Research Site
Jacksonville, Florida
Research Site
Saint Augustine, Florida
Research Site
Normal, Illinois
Research Site
Iowa City, Iowa
Research Site
Topeka, Kansas
Research Site
White Marsh, Maryland
Research Site
Boston, Massachusetts
Research Site
Chesterfield, Michigan
Research Site
Lincoln, Nebraska
Research Site
Ocean City, New Jersey
Research Site
Brooklyn, New York
Research Site
Chapel Hill, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Philadelphia, Pennsylvania
Research Site
Uniontown, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Houston, Texas
Research Site
Salt Lake City, Utah
Research Site
Salt Lake City, Utah
Research Site
Elizabeth Vale, Australia
Research Site
Kogarah, Australia
Research Site
South Brisbane, Australia
Research Site
Woolloongabba, Australia
Research Site
Vienna, Austria
Research Site
Wels, Austria
Research Site
Bruges, Belgium
Research Site
Edegem, Belgium
Research Site
Ghent, Belgium
Research Site
Leuven, Belgium
Research Site
Botucatu, Brazil
Research Site
Brasília, Brazil
Research Site
Caxias do Sul, Brazil
Research Site
Curitiba, Brazil
Research Site
Curitiba, Brazil
Research Site
Porto Alegre, Brazil
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.